CME/CE - PACE-CME

33-48 of 160

MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP; Leonie Kraft, MD
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
CKD-aP or Something Else? Decoding the Diagnosis
CKD-aP or Something Else? Decoding the Diagnosis
MinuteCE®
CKD-aP or Something Else? Decoding the Diagnosis
James Burton, DM, FRCP; Emilio Sanchez, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
CKD-aP Treatment Tool Kit 
CKD-aP Treatment Tool Kit 
MinuteCE®
CKD-aP Treatment Tool Kit 
Leonie Kraft, MD; Emilio Sanchez, MD, PhD
1.00 program credit
- Leonie Kraft, MD
- Emilio Sanchez, MD, PhD
1.00 program credit
Quantifying CKD-aP: Tools for Better Care 
Quantifying CKD-aP: Tools for Better Care 
MinuteCE®
Quantifying CKD-aP: Tools for Better Care 
James Burton, DM, FRCP; Emilio Sanchez, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
Elevating CKD-aP Care: New Frontier 
Elevating CKD-aP Care: New Frontier 
MinuteCE®
Elevating CKD-aP Care: New Frontier 
James Burton, DM, FRCP; Lucio Manenti, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Lucio Manenti, MD, PhD
1.00 program credit
CKD-aP: Beyond the Surface
CKD-aP: Beyond the Surface
MinuteCE®
CKD-aP: Beyond the Surface
Leonie Kraft, MD
1.00 program credit
- Leonie Kraft, MD
1.00 program credit
Is CKD-aP Hiding in Your Dialysis Center?
Is CKD-aP Hiding in Your Dialysis Center?
MinuteCE®
Is CKD-aP Hiding in Your Dialysis Center?
James Burton, DM, FRCP; Emilio Sanchez, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Iacopo Olivotto, MD; Ahmad Masri, MD, MS
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
CME/CE
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Irene Caruso
- Irene Caruso
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Prof. Ulrich Laufs; Pam R. Taub, MD, FACC, FASPC
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
Milind Y. Desai, MD, MBA; Iacopo Olivotto, MD
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
John McMurray, OBE, BSc, MB ChB (Hons), MD, FRCP, FRSE, FMedSci, FESC, FACC, FAHA, FJCS, FHFA, FHFSA, FBSH; Scott Solomon, MD
0.25 credits
- John McMurray, OBE, BSc, MB ChB (Hons), MD, FRCP, FRSE, FMedSci, FESC, FACC, FAHA, FJCS, FHFA, FHFSA, FBSH
- Scott Solomon, MD
0.25 credits
The Critical Interplay: CKD, HF, and HyperkaleAmia
The Critical Interplay: CKD, HF, and HyperkaleAmia
MinuteCE®
The Critical Interplay: CKD, HF, and HyperkaleAmia
James Burton, DM, FRCP; Javed Butler, MD
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
MinuteCE®
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Future Directions in Managing Hyperkalemia in CKD and HF
Future Directions in Managing Hyperkalemia in CKD and HF
MinuteCE®
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA; James Burton, DM, FRCP
1.00 program credit
- Javed Butler, MD, MPH, MBA
- James Burton, DM, FRCP
1.00 program credit
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
MinuteCE®
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit

3/8